Avelumab maintenance with axitinib interruption was feasible in metastatic renal cell carcinoma responders, according to ...

On Tuesday, the European Commission (EC) conditionally approved Merck & Co Inc’s (NYSE:MRK) Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, as monotherapy for: Adult ...

There are currently 82,000 incident cases of RCC annually in the United States (account for 3–5% of cancers), with 15,000 deaths annually in the United States. The overall 5-year mortality risk is ~30 ...

In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with significantly longer disease-free survival than placebo (24 months: 77% vs. 68%; ...

The following is a summary of “Risk factors for renal insufficiency and survival implications after radical nephrectomy and ...

PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.

Obinutuzumab B-cell depleting therapy is more effective than standard care in treating patients with active proliferative lupus nephritis.

The EC has conditionally approved MSD's Welireg as a single agent for the treatment of adults with VHL disease and advanced ...

AVEO Oncology, an LG Chem company ("AVEO"), is a biopharmaceutical company that is trying to provide differentiated solutions to improve cancer patients lives, presented two posters during the ...

The Company Invites Investors, Industry Executives, and Analysts to Attend Its Real-time, Interactive Presentation SAN DIEGO, CA - February 18, 2025 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. ("Sigyn" ...

Merck , known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), Merck's oral hypoxia-inducible ...

Merck (MRK) announced that the European Commission has conditionally approved WELIREG, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, ...